目的 对某院抗肿瘤靶向药物阿帕替尼临床应用情况进行回顾性调查分析并评价。方法 调取某院2015 年4月~2016 年3月使用阿帕替尼的病例,评价其用药合理性及安全性。结果 2015 年4月~2016 年3月使用阿帕替尼的患者84 例,符合药品说明书适应证有15例(占15.48%) ,不良反应主要为消化系统、高血压、皮肤毒性反应及骨髓抑制。结论 阿帕替尼在临床应用中存在超说明书适应证用药、用法用量不适宜,临床上应高度重视该药的合理使用,临床药师应以此为工作切入点,提高药物治疗的安全性和有效性,促进临床合理用药。
Abstract
OBJECTIVE To evaluate retrospectively the clinical application of apatinib in a hospital. METHODS The medical records including apatinib were collected during April 2015 to March 2016. Then, the rationality and safety of drug use were evaluated. RESULTS The 84 patients used apatinib during this time, while 15.48% (15 patients) conformed to the approved indications. The major adverse reactions were gastrointestinal disorders, hypertension, skin disorders and myelosuppression. CONCLUSION Irrational use of apatinib such as off-label use, inadequate usage and dosage exists in clinic. Clinicians should pay close attention to the rationality of apatinib, and clinical pharmacists can improve the safety and effectiveness of therapeutic drugs by taking this as the breakthrough point.
关键词
阿帕替尼 /
靶向药物 /
合理用药 /
临床药师
{{custom_keyword}} /
Key words
apatinib /
targeted therapy /
rational application /
clinical pharmacist
{{custom_keyword}} /
中图分类号：
R979
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LI J, QIN S K, XU J M, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1454.
[2] HU X H, CAO J, HU W W. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer [J]. BMC Cancer, 2014, 14:820.
[3] HU X C, ZHANG J, XU B H. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J]. Int J Cancer, 2014, 135(8):1961-1969.
[4] TIAN S, QUAN H, XIE C, et al. YN968DI is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo [J]. Cancer Sci, 2011, 102(7): 1374-1380.
[5] LIANG Y, BREKKEN R A, HYDER S M. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones[J]. Endocr Relat Cancer, 2006, 13(3):905-919.
[6] ZHANG L,SHI M Q,HUANG C,et al. A phase Ⅱ,multicenter,placebo-controlled trial of apatinib in patients withadvanced nonsquamous non-small cell lung cancer(NSCLC) after two previous treatment regimens [J]. J Clin Oncol,2012,30(suppl):abstr 7548.
[7] QIN S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase Ⅱ randomized, open-label trial[J]. J Clin Oncol,2014, 32(5S):abstr 4019.
[8] LI L L, HUA H Q. Second-line therapy for patients with hepatocellular carcinoma resisting to sorafinib[J]. Chin Clin Oncol(临床肿瘤学杂志),2014,19(6):556-559.
[9] JI G H, HONG L, YANG P. Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report[J]. Onco Targets Thera, 2016,9:643-647. doi:10.2147/OTT.S96133.
[10] YANG X N, WU Y L. Level of evidence and grades of recommendations[J]. J Evid Bas Med(循证医学),2003,3(2):111-113.
[11] JAIN R K, DI TOMASO E, DUDA D G, et al. Angiogenesis in brain tumours[J]. Nat Rev Neurosci,2007, 8(8):610-622.
[12] KUNKEL P, ULBRICHT U, BOHLEN P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2[J]. Cancer Res, 2001,61(18):6624-6628.
[13] DU R, LU K V, PETRITSCH C, et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion [J]. Cancer Cell, 2008,13(3):206-220.
[14] VERHEUL H M, PINEDO H M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition[J]. Nat Rev Cancer, 2007, 7(6): 475-485.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(652 KB)
